AFAndreas Fellgiebel

Andreas Fellgiebel

*This is an algorithmically generated author record based on publicly available information.

Andreas Fellgiebel has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Diffusion Tensor Imaging of the Hippocampus in MCI and Early Alzheimer's Disease

    by Andreas Fellgiebel, Igor Yakushev

    The hippocampus is among the first brain structures to be affected by Alzheimer's disease (AD) pathology. Microstructural alterations within this region have been quantified in vivo using diffusion tensor imaging (DTI), a relatively novel MRI-based t


  • Hippocampal atrophy as a surrogate of neuronal involvement in Fabry disease

    by Andreas Fellgiebel, Dominik O. Wolf, Edwin Kolodny, Matthias J. Müller

    Cerebral micro‐ and macro‐vasculopathy have been described in Fabry disease (FD). Neuronal globotriaosylceramide accumulation in selective cortical and brain stem areas including the hippocampus has been reported by autopsy studies in FD, but clinical surrogates as well as the clinical relevance of these findings have not been investigated so far. We measured the hippocampus volumes in a group of clinically affected patients with FD and correlated the findings with the cognitive performance of the patients. Hippocampal volumes were determined manually on T1‐weighted MR‐images of 25 FD patients (age 36.5 ± 11.0 years) and 20 age‐matched controls. Additionally, individual white matter (WM) and gray matter (GM) volumes were measured using brain segmentation analyses. After controlling for age, white matter lesion (WML) volume, and WM/GM‐volumes hippocampal volumes were significantly decreased in FD. These findings were substantially more pronounced in a subgroup of men with FD. WM and WM/GM volumes, and memory function did not significantly differ between patients and controls. In patients with FD hippocampal volumes were neither significantly correlated to WML volume nor to WM or WM/GM volumes. Hippocampus atrophy was not driven by the WML or other brain tissue atrophy and seems to correlate with the neuronal involvement in FD. In this young to middle‐aged Fabry cohort the hippocampus degeneration was functionally compensated without memory impairment. Longitudinal studies are needed to determine whether this degenerative component in FD will progress and, in concert with the individual WML‐load, predict subsequent cognitive decline.


  • Basilar Artery Diameter Is a Potential Screening Tool for Fabry Disease in Young Stroke Patients

    by Andreas Fellgiebel, Isabel Keller, Peter Martus, Stefan Ropele, Igor Yakushev, Tobias Böttcher, Franz Fazekas, Arndt Rolfs

    Background: Fabry disease (FD) is a rare hereditary lysosomal storage disease that has been highlighted as a possible etiology of stroke at a young age. Enlarged basilar artery diameters (BADs) have been demonstrated in FD, and we hypothesize that they might be useful for the screening of FD in young stroke patients. The aim of this study was to compare BADs of young stroke patients without FD to those of FD patients and of healthy age-matched controls. Methods: BADs were measured using MR angiography in 3 age- and gender-matched groups: 25 FD patients (aged 36.5 ± 11.0 years), 26 non-FD stroke patients and 20 healthy controls. Results: Compared to the non-FD stroke patients, FD patients had significantly enlarged BADs. FD patients could be significantly separated from stroke patients by BADs (area under the curve = 0.89, 95% confidence interval 0.81–0.98). Eighty-six percent of all subjects could be correctly classified by BADs (sensitivity 84%, specificity 88.5%). Conclusions: Enlarged BADs were able to detect FD within a cohort of FD, stroke patients and healthy controls. BAD measurement could be an easily obtainable and sensitive screening tool for FD in young stroke patients.


  • Diagnostic utility of different MRI and MR angiography measures in Fabry disease

    by A. Fellgiebel, I. Keller, D. Marin, M. J. MülLer, I. Schermuly, I. Yakushev, J. Albrecht, H. BellhäuSer, M. Kinateder, M. Beck, et al.

    Background: Neurologic hallmarks of Fabry disease (FD) include small fiber neuropathy as well as cerebral micro- and macroangiopathy with premature stroke. Cranial MRI shows progressive white matter lesions (WML) at an early age, increased signal intensity in the pulvinar, and tortuosity and dilatation of the larger vessels. To unravel the most promising imaging tool for the detection of CNS involvement in FD we compared the diagnostic utility of the different MR imaging findings.


  • FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment

    by Andreas Fellgiebel, Armin Scheurich, Peter Bartenstein, Matthias J Müller


  • Quantification of brain tissue alterations in Fabry disease using diffusion‐tensor imaging

    by Andreas Fellgiebel, Juliane Albrecht, Paulo R Dellani, Ingrid Schermuly, Peter Stoeter, Matthias J Müller

    Central nervous system involvement is a major burden in Fabry disease. Conventional cranial magnetic resonance imaging (MRI) shows micro‐ and macroangiopathic changes such as severe and progressive white matter lesions (WMLs) at an early age on T2‐ and fluid‐attenuated inversion recovery‐weighted images, increased signal intensity in the pulvinar on T1‐weighted MRI, as well as tortuosity and dilatation of the larger vessels (dolicho‐ectasia). Using diffusion tensor imaging (DTI), a new structural MRI‐technique that measures water diffusion characteristics, we showed marked brain tissue alterations in Fabry disease predominantly in the periventricular white matter. Even patients with few WMLs had significantly elevated brain tissue diffusivity.Conclusion: DTI is more sensitive in detecting brain tissue changes in Fabry disease than conventional MRI. DTI measurements could provide appropriate surrogate parameters with which to monitor the natural history of structural brain involvement and potential effects of therapy (such as enzyme replacement) in Fabry disease.


    • 1 January 2007
      • Vol. 21  (3) , 230-3

    [Alzheimer drugs for mild cognitive impairment].

    by Andreas Fellgiebel

    Improved diagnostic procedures allow to detect more patients with early stages of Alzheimer's disease (AD) within the increasing old population especially in the setting of specialised Memory Clinics. As no disease modifying or secondary preventive pharmacological treatments are presently available for AD this article discusses whether the established pharmacological treatment strategies for Alzheimer's dementia (DAT) could be beneficial as well for patients with amnestic mild cognitive impairment (MCI) that can be regarded a transitional stage between normal aging and DAT in many patients. The author does not recommend to treat MCI patients with Cholinesterase Inhibitors (ChE-I) or memantine first of all due to the general problems of a low specificity of the MCI concept and the missing data concerning the treatment of MCI patients with memantine. Moreover, ChE-I therapy in MCI showed weak beneficial effects on cognition and the delay of DAT onset whereas it is costly and has a high risk of side effects. Additionally, the pooled galantamin-data suggest an increased mortality compared to placebo. Finally, cortical cholinergic deficits and the corresponding cognitive deficits are commonly not present in MCI.


  • Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism

    by Andreas Fellgiebel, Matthias J. Müller, Christoph Hiemke, Peter Bartenstein, Matthias Schreckenberger

    Frontotemporal dementia (FTD) is increasingly recognized as an important type of degenerative dementia but satisfactory pharmacological treatment has not yet been established. We examined the clinical effects of aripiprazole, a new antipsychotic with partial agonistic properties at serotonin 5-HT(1A) and dopamine D(2) receptors, in parallel with cortical glucose metabolism changes. We conducted a follow-up investigation of clinical status and (18)F-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) in a 73-year-old male patient with FTD over a 13-month period. Under conventional drug treatment during the first 12 months a marked increase in dementia symptoms was observed. Frontal lobe glucose metabolism clearly decreased during this time period. Under consecutive treatment with aripiprazole a significant and stable improvement of clinical symptoms could be registered, while disturbed frontal glucose metabolism increased significantly. According to this case experience, further investigations should be undertaken to ascertain whether aripiprazole or other atypical antipsychotics with properties to improve impaired dopaminergic transmission in frontal brain regions could qualify for therapy of FTD.